What Happened When California Let Glaucoma Patients Try THC
A California compassionate access program enrolled only 9 glaucoma patients despite strong physician interest, and all discontinued treatment within 9 months due to side effects and unsustained pressure reduction.
Quick Facts
What This Study Found
Despite 20 approved ophthalmologist investigators and strong initial interest, only 9 patients enrolled in the Cannabis Therapeutic Research Program. All patients showed an initial decrease in intraocular pressure, and treatment goals were met in 4 of the 9 patients. However, the pressure reductions were not sustained over time, and every patient elected to discontinue treatment within 1 to 9 months.
Reasons for discontinuation were varied but related to the development of tolerance to the pressure-lowering effect and significant systemic side effects. The authors concluded that while cannabinoids can lower eye pressure, tolerance and toxicity appeared to limit their usefulness as a glaucoma treatment.
Key Numbers
Twenty ophthalmologists were approved as investigators. Nine patients enrolled. Four of nine met the investigator's therapeutic goal initially. All nine discontinued treatment within 1 to 9 months.
How They Did This
This was an uncontrolled, unmasked, nonrandomized study conducted under the California Cannabis Therapeutic Research Program. Patients with end-stage glaucoma unresponsive to conventional treatments received either oral THC capsules or inhaled marijuana alongside their existing treatment regimen. The program was designed for compassionate access rather than rigorous clinical investigation.
Why This Research Matters
This real-world program provided a rare look at what happened when glaucoma patients actually tried cannabinoid treatment over months rather than in single-dose laboratory studies. The finding that all patients voluntarily stopped treatment due to tolerance and side effects was a powerful practical counterpoint to the common belief that cannabis is an effective glaucoma treatment.
The Bigger Picture
This study reinforced what other research was finding: while cannabinoids can acutely lower eye pressure, the effect does not last, tolerance develops, and side effects accumulate. Major ophthalmological organizations subsequently issued statements against recommending cannabis for glaucoma, citing these limitations.
What This Study Doesn't Tell Us
The uncontrolled, unmasked design prevents definitive conclusions about efficacy. The very small sample (9 patients) limits generalizability. The program enrolled only end-stage, treatment-resistant patients who may not represent typical glaucoma cases. No standardized outcome measures or dosing protocols were described.
Questions This Raises
- ?Why was enrollment so low despite strong physician interest?
- ?Would different cannabinoid formulations or delivery methods have produced more sustained effects?
- ?Could cannabinoids play a complementary role at lower doses alongside conventional treatments?
Trust & Context
- Key Stat:
- All 9 patients discontinued THC treatment within 1-9 months
- Evidence Grade:
- This was an uncontrolled compassionate access program with only 9 patients and no comparison group, providing preliminary-level evidence.
- Study Age:
- Published in 2002. Major ophthalmological organizations have since issued statements against cannabis as a glaucoma treatment.
- Original Title:
- Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma.
- Published In:
- Transactions of the American Ophthalmological Society, 100, 215-22; discussion 222-4 (2002)
- Authors:
- Flach, Allan J
- Database ID:
- RTHC-00119
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Why don't eye doctors recommend cannabis for glaucoma?
This study showed the practical problems: while cannabis initially lowers eye pressure, the effect fades as tolerance develops, side effects accumulate, and patients stop treatment. Glaucoma requires consistent 24-hour pressure control that cannabis cannot provide.
Why did so few patients enroll when many doctors were interested?
The paper noted the disconnect between physician interest and actual enrollment but did not fully explain it. Possible factors include patient reluctance, strict eligibility criteria (end-stage disease only), and the challenges of participating in a regulated cannabis program.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00119APA
Flach, Allan J. (2002). Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma.. Transactions of the American Ophthalmological Society, 100, 215-22; discussion 222-4.
MLA
Flach, Allan J. "Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma.." Transactions of the American Ophthalmological Society, 2002.
RethinkTHC
RethinkTHC Research Database. "Delta-9-tetrahydrocannabinol (THC) in the treatment of end-s..." RTHC-00119. Retrieved from https://rethinkthc.com/research/flach-2002-delta9tetrahydrocannabinol-thc-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.